• Goldenwell Biotech restated its quarterly financial statements for the quarter ended Sept. 30, 2025 in a Form 10-Q/A filed June 29, 2026.
• Restatement removed USD 25,000 of service revenue previously recorded for the quarter, tied to a service contract that did not meet recognition criteria.
• Quarterly net loss was restated to USD 27,895 from USD 7,985, reflecting revised revenue timing, legal expense accrual timing, and OTCQB fee deferral.
• Balance sheet changes included a USD 13,350 prepaid OTCQB fee asset and unearned service revenue increased to USD 100,000 from USD 37,500.
• As of Sept. 30, 2025, the restated balance sheet showed USD 233,760 in assets, USD 377,733 in liabilities, and stockholders’ deficit of USD 143,974.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Goldenwell Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004067), on June 29, 2026, and is solely responsible for the information contained therein.